Compilation of Scientific Data for Newly CDSCO-Approved Antidiabetic Drugs in Last Five Years: A Review

Abstract

Diabetes is a substantial medical problem that is increasing globally due to a rise in sedentary lifestyles, unhealthy eating habits, and obesity rates. There is a tight relationship between diabetes with obesity. Several epidemiological studies suggested that 80% of T2D patients are obese or overweight. Indeed, the immune system assaults the pancreatic beta cells that produce insulin in T1D, an autoimmune disease. High blood sugar levels occur when the body generates very little insulin. is frequently linked to unhealthy habits, including not getting enough exercise, eating poorly, and being overweight. Heart disease, diabetic neuropathy, kidney problems, ketoacidosis, and nerve damage are only some of the many health consequences that are more common with both types. Antidiabetic drugs like metformin can be used to lower the blood glucose level. Sulfonylureas, glinides, and thiazolidinediones are some most common oral antidiabetics (OADs), and for newly analyzed type 2 diabetes, glucosidase inhibitors are cost-effective strategies to improve glycaemic control. As a second line of defense against T2D, you may be prescribed an enzyme inhibitor (DPP-4i), an inhibitor of renal SGLT-2i, or an agonist for glucagon-like peptide-1 receptor. Poor adherence to oral antidiabetic medication regimens is associated with therapy failure and other consequences in patients with type 2 diabetes, which is a collective medical problem. Acarbose, miglitol, alogliptin, sitagliptin, sitagliptin-metformin, tirzepatide, liraglutide, nateglinide, rapeglinide, dopagliflozin, empagliflozin-metformin, glipizide-metformin, glimepiride-pioglitazone, glipizide, rosiglitazone, pioglitazone-alogliptin, and pioglitazone-metformin, among other antidiabetic medications, have been approved for use in India by CDSCO. All across the world, regulatory bodies are in charge of making sure that pharmaceuticals are safe, effective, and up to par at every stage of the drug lifecycle, from development to manufacture to marketing. Their job is to keep the public healthy